Abstract: The present invention is directed to inorganic oxide particles that have been modified with a chelator group. In an embodiment, the chelator group is covalently bonded to a polymer. In an embodiment, the chelator group is covalently bonded to a chiral selector ligand. The present invention is also directed to methods of modifying inorganic oxide particles with a chelator group.

Abstract: The present invention describes the use of porous metal oxides for the preparative purification of antibodies and biomolecules within a range of particle physical characteristics. Typically, particles from 15 to 100 microns in average diameter with pores sizes ranging from 400 to 600 angstroms and surface areas from 10 to 50 square meters per gram, and pore volumes from 0.1 to 0.4 mL/gram can be used for purification processes. The metal oxide particles that fall within this range of physical properties show enhanced utility and greater chromatographic capacity for antibodies than materials oxide particles falling outside of this range. Metal oxides such as zirconia, titania and alumina can all be modified with a multi-Lewis base moiety such as an organophosphate ethylenediamine-N,N-tetra(methylenephosphonic) acid (EDTPA), to produce a bio-compatible purification media for, biomolecules.